Neurotransmitter-mediated anxiogenic action of PACAP-38 in rats

Behavioural Brain Research

Volumn 281, Issue , 2015, Pages 333-338s

  Telegdy, G ^a   Adamik, A ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Anxiety; Male rats; Neurotransmitter mediation; PACAP 38

Indexed keywords

ATROPINE; BICUCULLINE; DOPAMINE RECEPTOR; HALOPERIDOL; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; METHYSERGIDE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OPIATE RECEPTOR; PHENOXYBENZAMINE; PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 38; PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE [6-38]; PROPRANOLOL; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; ADRENERGIC RECEPTOR BLOCKING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N-NITROSOARGININE; NARCOTIC ANTAGONIST; NITROSO DERIVATIVE; PEPTIDE FRAGMENT; PITUITARY ADENYLATE-CYCLASE-ACTIVATING-PEPTIDE (6-38); SEROTONIN 2 ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; ELEVATED PLUS MAZE TEST; ENZYME INHIBITION; LATERAL BRAIN VENTRICLE; MALE; NONHUMAN; RAT; RECEPTOR BLOCKING; SEROTONINERGIC TRANSMISSION; TRANQUILIZING ACTIVITY; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG EFFECTS; DRUG THERAPY; EXPLORATORY BEHAVIOR; MAZE TEST; METABOLISM; WISTAR RAT;

ADRENERGIC ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANXIETY; ARGININE; ATROPINE; BICUCULLINE; DOPAMINE ANTAGONISTS; EXPLORATORY BEHAVIOR; HALOPERIDOL; MALE; MAZE LEARNING; METHYSERGIDE; MUSCARINIC ANTAGONISTS; NALOXONE; NARCOTIC ANTAGONISTS; NEUROTRANSMITTER AGENTS; NITROSO COMPOUNDS; PEPTIDE FRAGMENTS; PHENOXYBENZAMINE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROPRANOLOL; RATS; RATS, WISTAR; RECEPTORS, GABA; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84920897057     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.12.039     Document Type: Article

References (38)

1. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate-cyclase in pituitary cells. Biochem Biophys Res Commun 1989, 164:567-574.
2. Miyata A., Jiang L., Dahl R.R., Kitada C., Kubo K., Fujino M., et al. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP-38). Biochem Biophys Res Commun 1990, 170:643-648.
3. Arimura A., Somogyvári-Vigh A., Miyata A., Mizumo K., Coy D.H., Kitada C. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 1991, 129:2787-2789.
4. Köves K., Arimura A., Görcs T.G., Somogyvári-Vígh A. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 1991, 54:159-169.
5. Cauvin A., Robberecht P., De Neef P., Gourlet P., Vandermeers A., Vandermeers-Piret M.C., et al. Properties and distribution of receptors for pituitary adenylate cyclase activating peptide (PACAP) in rat brain and spinal cord. Regul Pept 1991, 35:161-163.
6. Masuo Y., Noguchi J., Morita S., Matsumoto Y. Effects of intracerebroventricular administration of pituitary adenylate cyclase-activating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines 1995, 700:219-226.
7. Ghatei A., Takahashi K., Suzuki Y., Gardiner J., Jones P.M., Bloom S.R. Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 1993, 136:159-166.
8. Tatsuno I., Gottschall P.E., Köves K., Arimura A. Demonstration of specific binding sites for pituitary adenylate cyclase activating polypeptide (PACAP) in rat astrocytes. Biochem Biophys Res Commun 1990, 168:1027-1033.
9. Ashur-Fabian O., Giladi E., Brenneman D.E., Gozes I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodesoxynucleotides. J Mol Neurosci 1997, 9:211-222.
10. Harmar A.J., Fahrenkrug J., Gozes I., Laburthe M., May V., Pisegna J.R., et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1 International Union of Basic and Clinical Pharmacology Review. Br J Pharmacol 2012, 166:4-17.
11. Telegdy G., Kokavszky K. The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of transmitters. Brain Res 2000, 874:194-199.
12. Adamik A., Telegdy G. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on extinction of active avoidance learning in rats: involvement of neurotransmitters. Regul Pept 2005, 127:55-62.
13. Sacchetti B., Lorenzini C.A., Baldi R., Bucherelli C., Roberto M., Tassoni G., et al. Pituitary adenylate cyclase activating polypeptide hormone (PACAP) at very low dosages improves memory in the rat. Neurobiol Learn Mem 2001, 76:1-6.
14. Sauvage M., Brabet P., Holsboer F., Bockaert J., Steckler T. Mild deficit in mice lacking pituitary adenylate cyclase-activating polypeptide receptor type 1 (PAC1) performing on memory tasks. Brain Res Mol Brain Res 2000, 8:79-89.
15. Otto C., Kovalchuk Y., Wolfer D.P., Gass P., Martin M., Zuschratter W., et al. Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J Neurosci 2001, 21:5520-5527.
16. Pataki I., Adamik A., Jászberényi M., Mácsai M., Telegdy G. Pituitary adenylate cyclase activating polypeptide induces hyperthermia in rats. Neuropharmacology 2000, 39:1303-1308.
17. Pataki I., Adamik A., Jászberényi M., Mácsai M., Telegdy G. Involvement of transmitters in pituitary adenylate cyclase activating polypeptide induces hyperthermia. Regul Pept 2003, 115:187-193.
18. Morley J., Horowitz M., Morley P.M.K., Flood J.F. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides 1992, 13:1133-1135.
19. Chance W.T., Thompson H., Thomas I., Fischer J.E. Anorectic and neurochemical effects of pituitary adenylate cyclase activating polypeptide in rats. Peptides 1995, 16:1511-1516.
20. Adamik A., Telegdy G. Involvement of different receptors in pituitary adenylate cyclase activating polypeptide induced open field activity in rats. Neuropeptides 2004, 38:16-20.
21. Farnham M.M., Lung M.S., Tallapragada V.J., Pilowsky P.M. PACAP causes PAC1/VPAC2receptor mediated hypertension and sympathoexcitation in normal and hypertensive rats. Am J Physiol Heart Circ Physiol 2012, 1(303):H910-H917.
22. Shen S., Gehlert D.R., Collier D.A. PACAP and PAC1 receptor in brain development and behavior. Neuropeptides 2013, 47(421):30.
23. Kanasaki H., Purwana I.N., Miyazaki K. Possible role of PACAP and its PAC1 receptor in the differential regulation of pituitary LHbeta- and FSHbeta-subunit gene expression by pulsatiy GnRH stimulation. Biol Reprod 2013, 88(2):35. 10.1095/biolreprod.112.105601.
24. Pinhasov A., Nesher E., Gross M., Kreinin A., Yadid G. The role of the PACAP signaling system in depression. Curr Pharm Des 2011, 17:990-1001.
25. Abad C., Waschek J.A. Immunomodulatory roles of VIP and PACAP in models of multiple sclerosis. Curr Pharm Des 2011, 17:1025-1035.
26. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A stereotactic atlas of the rat brain 1979, Plenum Press, New York.
27. Telegdy G., Tiricz H., Adamik A. Involvement of neurotransmitters in urocortin-induced passive avoidance learning in mice. Brain Res Bull 2005, 67:242-247.
28. Tanaka M., Csabafi K., Telegdy G. Neurotransmissions of antidepressant-like effects of kisspeptin-13. Regul Pept 2012, 228:388-391.
29. Pellow S., Chopin P., File S., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
30. Vaudry D., Gonzalez B.J., Basille M., Yon L., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2000, 52:269-324.
31. Vaudry D., Falluel-Morel A., Bourgalt S., Basille M., Burel D., Wurtz O., et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009, 61:283-357.
32. Telegdy G. Neuropeptides and brain function. Frontiers of hormone research 1984, vol. 15:1-332. Karger, Basel.
33. Hammack S.E., Cheung J., Rhodes K.M., Schutz K.C., Falls W.A., Braas K.M., et al. Chronic stress increases pituitary adenylate cyclase-activating peptide (PACAP) and brain-derived neurotropic factor (BDNF) mRNA expression in the bed nucleus of the stria terminalis (BNST)roles for PACAP in anxiety-like behavior. Psychoneuroendocrinology 2009, 34:833-843.
34. Gaszner B., Kormos V., Kozicz T., Hashimoto H., Reglödi D., Helyes Z. The behavioral phenotype of pituitary adenylate-cyclase activating polypeptide-deficient mice in anxiety and depression tests is accompanied by blunted c-Fos expression in the bed nucleus of the stria terminalis, central projecting Edinger-Westphal nucleus, ventral lateral septum and dorsal raphe nucleus. Neuroscience 2012, 202:283-299.
35. Dore R., Iemolo A., Smith K.L., Wang X., Cottone O.P., Sabino V. CRF mediates the anxiogenic and anti-rewarding, but not the anorectic effects of PACAP. Neuropsychopharmacology 2013, 38:2160-2169.
36. Adamik A., Telegdy G., Jászberényi M. Involvement of neurotransmitters in the action of apelin-13 on passive avoidance learning in mice. Peptides 2013, 39:171-174.
37. Biró E., Penke B., Telegdy G. Role of different neurotransmitter systems in the cholecytokinin octapeptide induced anxiogenic response in rats. Neuropeptide 1991, 31:273-280.
38. Palotai M., Telegdy G., Jászberényi M. Orexin A-induced anxiety-like behavior is mediated through GABA-ergic, α- and β-adrenergic neurotransmissions in mice. Peptides 2014, 57:129-134.